The DOI matches its Crossref record.
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Open accessAbstract
The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain. We show here that the drugs loperamide, domperidone, and ondansetron are transported substrates for the mouse mdr1a P-GP and its human homologue MDR1. Phenytoin is a relatively weaker substrate for each, and the drugs haloperidol, clozapine, and flunitrazepam are transported hardly or not at all. Tissue distribution studies demonstrated that the relative brain penetration of radiolabeled ondansetron and loperamide (and their metabolites) is increased four- and sevenfold, respectively, in mdr1a (-/-) mice. A pilot toxicity study with oral loperamide showed that this peripherally acting antidiarrheal agent gains potent opiatelike activity in the central nervous system of mdr1a (-/-) mice. mdr1a (-/-) mice also showed increased sensitivity to neurolepticlike side effects of oral domperidone. These results point to the possible role that the drug-transporting P-GP(s) may play in the clinical use of many drugs, especially those with potential targets in the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
High throughput artificial membrane permeability assay for blood–brain barrier
Di, L., Kerns, E. H., Fan, K., McConnell, O. J., & Carter, G. T. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00012-6 · Cited by 1,195
Chemogenetics revealed: DREADD occupancy and activation via converted clozapine
Gomez, J. L., Bonaventura, J., Lesniak, W., Mathews, W. B., Sysa-Shah, P., Rodriguez, L. A., Ellis, R. J., Richie, C. T., Harvey, B. K., Dannals, R. F., et al. (2017) · Science · doi:10.1126/science.aan2475 · Cited by 980
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
The blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Genetic susceptibility to adverse drug reactions
Pirmohamed, M., & Park, B. K. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01717-x · Cited by 328
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Bauer, B., Hartz, A. M. S., & Miller, D. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029512 · Cited by 275
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Relationship Between P-Glycoprotein and Second-Generation Antipsychotics
Moons, T., de Roo, M., Claes, S., & Dom, G. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.55 · Cited by 122
Improved measurement of drug exposure in the brain using drug-specific correction for residual blood
Fridén, M., Ljungqvist, H., Middleton, B., Bredberg, U., & Hammarlund-Udenaes, M. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.200 · Cited by 114
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Investigation of the Influence of FcRn on the Distribution of IgG to the Brain
Garg, A., & Balthasar, J. P. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9129-9 · Cited by 108
The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse
Schaefer, C. P., Tome, M. E., & Davis, T. P. (2017) · Fluids and Barriers of the CNS · doi:10.1186/s12987-017-0080-3 · Cited by 83
Noble, F., & Marie, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00742 · Cited by 56
Terry, G., Liow, J.-S., Chernet, E., Zoghbi, S. S., Phebus, L., Felder, C. C., Tauscher, J., Schaus, J. M., Pike, V. W., Halldin, C., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.004 · Cited by 51
Akanuma, S.-I., Hori, S., Ohtsuki, S., Fujiyoshi, M., & Terasaki, T. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.08.012 · Cited by 43
Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia
Roy-Desruisseaux, J., Landry, J., Bocti, C., Tessier, D., Hottin, P., & Trudel, J.-F. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q214 · Cited by 32
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions
Stern, E. R., Shahab, R., Grimaldi, S. J., Leibu, E., Murrough, J. W., Fleysher, L., Parides, M. K., Coffey, B. J., Burdick, K. E., & Goodman, W. K. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0174-x · Cited by 27
Structural insights into binding-site access and ligand recognition by human ABCB1
Kurre, D., Dang, P. X., Le, L. T. M., Gadkari, V. V., & Alam, A. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00361-z · Cited by 25
Heikkinen, A. T., Fowler, S., Gray, L., Li, J., Peng, Y., Yadava, P., Railkar, A., & Parrott, N. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300692k · Cited by 20
Dorninger, F., Vaz, F. M., Waterham, H. R., Klinken, J. B. V., Zeitler, G., Forss-Petter, S., Berger, J., & Wiesinger, C. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.08.006 · Cited by 12
Metadata
- Authors
- Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L.
- Venue
- Journal of Clinical Investigation
- Published
- 1996-06-01
- Volume
- 97
- Issue
- 11
- Pages
- 2517-2524
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2021759214
- Cited by
- 1,264
- References
- 0
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
